Share This

Topics Comments

Cheung Kong VODone Limited Shenzhen International Holdings Limited Jiangxi Copper Company Limited REXLot Holdings Limited China Overseas Land & Investment Limited Chong Hing Bank Limited Agricultural Bank of China Limited Chow Tai Fook Jewellery Group Limited Capital VC Limited iShares A50 Standard Chartered Bank of Communications Bank of China China LotSynergy Holdings Limited agribank Agri Airlines Appl AUD Auto A Shares Brokers CAD fertilizer producers China Lottery Supermarket China Banks Communication Consumer China Econ Electricity China Finance China IT Petro Real Est China Resource Steel coal Commodity Beauty Drugs Enviro EURO Lang Simon Ting WongSir Andy Xie Expo Gambling Garment gas GBD Gold Gold Jew Gold mine Harbour Highways HK Apparel REITs Rentals HK Banks ETF HK Housing Market Real Est HK HK Stock iBond Infra Insure IPO jewel Mach Build Mat New Energy NZD Oil Paper Rare Earths Real Estate Market Food RMB Rising RMB RMB Bonds Shipbuilding Shipping Sports Stock Trend Taiwan Dollar (TWD) Textile Top 500 USD US Econ Util Water Yang Liu's 10 Stocks YEN Diary media Central Bank Monetary Policy Education Construction Emerging markets Nuclear power BillGross Cement HK retail logistics Swiss franc Social Security Fund Law Ka-Chung capital flow Financial and political policy Railway film Korean Won Roubini Faber Mobius
Topics Last reply time Nickname Content
GENSCRIPT BIOTECH CORPORATION 2019-04-09T10:34 財經茄呢啡 金斯瑞生物(1548)與美國強生的製藥業務楊森,共同開發用於治療多發性骨髓瘤藥物,獲歐洲藥品管理局以優先審評藥物認定,消息刺激金瑞斯昨日股價急漲25.5%,收19.2元。
GENSCRIPT BIOTECH CORPORATION 2018-09-29T08:33 財經茄呢啡 金斯瑞(1548)前日被沽空機構閻火研究指數據造假,股價插水27%後停牌。金斯瑞昨發公告強硬否認所有指控,再在場內以每股介乎13.5元至13.6元,斥資271萬元,回購20萬股股份。股份昨復牌,股價反彈11.5%,收報13.2元。
GENSCRIPT BIOTECH CORPORATION 2017-12-14T08:35 財經茄呢啡 12月11日,藥監總局宣佈受理金斯瑞生物科技(1548)抗癌新藥CAR-T審批,CAR-T採用細胞免疫療法,針對癌症末期病人,美國同類藥售價約40萬美元,國際上市場潛力極大。金斯瑞本月股價已飆升近3成。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.